Benzimidazoles as benzamide replacements within cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists. 2012

Robert J Cherney, and Ruowei Mo, and Dayton T Meyer, and Anthony D Pechulis, and Michael A Guaciaro, and Yvonne C Lo, and Gengjie Yang, and Persymphonie B Miller, and Peggy A Scherle, and Qihong Zhao, and Mary Ellen Cvijic, and Joel C Barrish, and Carl P Decicco, and Percy H Carter
Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States. robert.cherney@bms.com

We describe the design, synthesis, and evaluation of benzimidazoles as benzamide replacements within a series of trisubstituted cyclohexane CCR2 antagonists. 7-Trifluoromethylbenzimidazoles displayed potent binding and functional antagonism of CCR2 while being selective over CCR3. These benzimidazoles were also incorporated into lactam-containing antagonists, thus completely eliminating the customary bis-amide.

UI MeSH Term Description Entries
D008861 Microsomes Artifactual vesicles formed from the endoplasmic reticulum when cells are disrupted. They are isolated by differential centrifugation and are composed of three structural features: rough vesicles, smooth vesicles, and ribosomes. Numerous enzyme activities are associated with the microsomal fraction. (Glick, Glossary of Biochemistry and Molecular Biology, 1990; from Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) Microsome
D003510 Cyclohexanes Six-carbon alicyclic hydrocarbons.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D054390 Receptors, CCR2 CCR receptors with specificity for CHEMOKINE CCL2 and several other CCL2-related chemokines. They are expressed at high levels in T-LYMPHOCYTES; B-LYMPHOCYTES; MACROPHAGES; BASOPHILS; and NK CELLS. Antigens, CD192,CC Chemokine Receptor 2,CCR2 Receptors,CD192 Antigens,CC CKR2B,CC Chemokine Receptor-2,CC Chemokine Receptors 2,CCR-2A MCP-1 Receptor,CCR2 Receptor,CCR2a Receptor,CCR2b Receptor,CCR2b Receptors,MCP-1 Receptor,MCP-1 Receptor 2B,MCP-1 Receptor CCR-2A,MCP-1 Receptors,MCP-1RA,MCP-1RB,Monocyte Chemoattractant Protein 1 Receptor,CCR 2A MCP 1 Receptor,Chemokine Receptor-2, CC,MCP 1 Receptor,MCP 1 Receptor 2B,MCP 1 Receptor CCR 2A,MCP 1 Receptors,MCP-1 Receptor, CCR-2A,Receptor CCR-2A, MCP-1,Receptor, CCR-2A MCP-1,Receptor, CCR2,Receptor, CCR2a,Receptor, CCR2b,Receptor, MCP-1,Receptor-2, CC Chemokine,Receptors, CCR2b,Receptors, MCP-1

Related Publications

Robert J Cherney, and Ruowei Mo, and Dayton T Meyer, and Anthony D Pechulis, and Michael A Guaciaro, and Yvonne C Lo, and Gengjie Yang, and Persymphonie B Miller, and Peggy A Scherle, and Qihong Zhao, and Mary Ellen Cvijic, and Joel C Barrish, and Carl P Decicco, and Percy H Carter
August 2006, Journal of medicinal chemistry,
Robert J Cherney, and Ruowei Mo, and Dayton T Meyer, and Anthony D Pechulis, and Michael A Guaciaro, and Yvonne C Lo, and Gengjie Yang, and Persymphonie B Miller, and Peggy A Scherle, and Qihong Zhao, and Mary Ellen Cvijic, and Joel C Barrish, and Carl P Decicco, and Percy H Carter
August 2007, Bioorganic & medicinal chemistry letters,
Robert J Cherney, and Ruowei Mo, and Dayton T Meyer, and Anthony D Pechulis, and Michael A Guaciaro, and Yvonne C Lo, and Gengjie Yang, and Persymphonie B Miller, and Peggy A Scherle, and Qihong Zhao, and Mary Ellen Cvijic, and Joel C Barrish, and Carl P Decicco, and Percy H Carter
September 2008, Bioorganic & medicinal chemistry letters,
Robert J Cherney, and Ruowei Mo, and Dayton T Meyer, and Anthony D Pechulis, and Michael A Guaciaro, and Yvonne C Lo, and Gengjie Yang, and Persymphonie B Miller, and Peggy A Scherle, and Qihong Zhao, and Mary Ellen Cvijic, and Joel C Barrish, and Carl P Decicco, and Percy H Carter
July 2015, Bioorganic & medicinal chemistry,
Robert J Cherney, and Ruowei Mo, and Dayton T Meyer, and Anthony D Pechulis, and Michael A Guaciaro, and Yvonne C Lo, and Gengjie Yang, and Persymphonie B Miller, and Peggy A Scherle, and Qihong Zhao, and Mary Ellen Cvijic, and Joel C Barrish, and Carl P Decicco, and Percy H Carter
February 2010, Expert opinion on therapeutic patents,
Robert J Cherney, and Ruowei Mo, and Dayton T Meyer, and Anthony D Pechulis, and Michael A Guaciaro, and Yvonne C Lo, and Gengjie Yang, and Persymphonie B Miller, and Peggy A Scherle, and Qihong Zhao, and Mary Ellen Cvijic, and Joel C Barrish, and Carl P Decicco, and Percy H Carter
October 2007, Bioorganic & medicinal chemistry letters,
Robert J Cherney, and Ruowei Mo, and Dayton T Meyer, and Anthony D Pechulis, and Michael A Guaciaro, and Yvonne C Lo, and Gengjie Yang, and Persymphonie B Miller, and Peggy A Scherle, and Qihong Zhao, and Mary Ellen Cvijic, and Joel C Barrish, and Carl P Decicco, and Percy H Carter
April 2010, Bioorganic & medicinal chemistry letters,
Robert J Cherney, and Ruowei Mo, and Dayton T Meyer, and Anthony D Pechulis, and Michael A Guaciaro, and Yvonne C Lo, and Gengjie Yang, and Persymphonie B Miller, and Peggy A Scherle, and Qihong Zhao, and Mary Ellen Cvijic, and Joel C Barrish, and Carl P Decicco, and Percy H Carter
December 2016, Nature,
Robert J Cherney, and Ruowei Mo, and Dayton T Meyer, and Anthony D Pechulis, and Michael A Guaciaro, and Yvonne C Lo, and Gengjie Yang, and Persymphonie B Miller, and Peggy A Scherle, and Qihong Zhao, and Mary Ellen Cvijic, and Joel C Barrish, and Carl P Decicco, and Percy H Carter
June 2005, Biochimica et biophysica acta,
Robert J Cherney, and Ruowei Mo, and Dayton T Meyer, and Anthony D Pechulis, and Michael A Guaciaro, and Yvonne C Lo, and Gengjie Yang, and Persymphonie B Miller, and Peggy A Scherle, and Qihong Zhao, and Mary Ellen Cvijic, and Joel C Barrish, and Carl P Decicco, and Percy H Carter
February 2005, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!